Health Care [ 12/12 ] | Health Care Equipment & Supplies [ 43/74 ]
NYSE | Common Stock
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands.
The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products.
This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings.
The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development.
The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984.
Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 23, 24 | 1.72 Decreased by -16.10% | 1.57 Increased by +9.55% |
| Apr 23, 24 | 1.92 Decreased by -18.64% | 1.71 Increased by +12.28% |
| Jan 30, 24 | 2.09 Decreased by -27.18% | 1.91 Increased by +9.42% |
| Oct 24, 23 | 2.02 Decreased by -21.09% | 1.87 Increased by +8.02% |
| Jul 25, 23 | 2.05 Decreased by -25.72% | 2.01 Increased by +1.99% |
| Apr 25, 23 | 2.36 Decreased by -14.49% | 2.25 Increased by +4.89% |
| Jan 24, 23 | 2.87 Increased by +6.69% | 2.54 Increased by +12.99% |
| Oct 20, 22 | 2.56 Increased by +7.11% | 2.26 Increased by +13.27% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 5.80 B Decreased by -15.64% | 818.00 M Decreased by -27.55% | Increased by +14.11% Decreased by -14.11% |
| Jun 30, 24 | 5.74 B Decreased by -19.76% | 907.00 M Decreased by -17.99% | Increased by +15.79% Increased by +2.20% |
| Mar 31, 24 | 5.80 B Decreased by -19.13% | 1.09 B Decreased by -24.97% | Increased by +18.77% Decreased by -7.22% |
| Dec 31, 23 | 2.69 B Decreased by -67.82% | 1.08 B Decreased by -51.66% | Increased by +40.07% Increased by +50.23% |
| Sep 30, 23 | 6.87 B Decreased by -10.31% | 1.13 B Decreased by -27.21% | Increased by +16.43% Decreased by -18.84% |
| Jun 30, 23 | 7.16 B Decreased by -7.66% | 1.11 B Decreased by -33.29% | Increased by +15.45% Decreased by -27.76% |
| Mar 31, 23 | 7.17 B Decreased by -6.78% | 1.45 B Decreased by -13.90% | Increased by +20.23% Decreased by -7.64% |
| Dec 31, 22 | 8.37 B Increased by +2.71% | 2.23 B Increased by +27.76% | Increased by +26.67% Increased by +24.39% |